Since 2014, NanoGuard Technologies has been at the forefront of innovative cold plasma solutions in the agricultural and medical industries. NanoGuard holds 4 global patents for HVACP technology in 28 countries.
We are at the forefront of developing novel sterilization methods that address the evolving needs of the industry. Our technology achieves a 6.0-log reduction of Bacillus atrophaeus spore strips, the same biological indicator used to validate sterilization of ethylene oxide and other modalities.
NanoGuard’s 15kW cold plasma system with commercial application in numerous industries.
Mycotoxin and microbial reduction – granted globally, with a limited non-exclusive license held by Bunge.
Virus treatment – granted in the US and EU, with global patents pending.
Plasma generator design – granted in the US and EU, with global patents pending.
Cost-effective treatment improvements – filed as a US provisional patent.
Our technology is highly scalable, allowing for expansion in the medical sterilization market, as well as in sterilization services and equipment sales. Additionally, NanoGuard’s core technology holds significant potential for growth and market diversification in sectors such as PFAS water treatment, cargo decontamination, and mycotoxin mitigation.
Subscribe to our newsletter and be the first to receive updates on cutting-edge sterilization technologies,from NanoGuard Technologies.
